HS-20117
- Generic Name
- HS-20117
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid TumorsColorectal CancerNon-Small Cell Lung Cancer
- Interventions
- Drug: Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 762
- Registration Number
- NCT06963502
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
🇨🇳Sun Yat-sen University Cancer Center, Shanghai, China
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Drug: Aumolertinib
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 1080
- Registration Number
- NCT06417008
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 322
- Registration Number
- NCT05940116
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath